Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Nanoparticle delivery of transition-metal chelators to the brain: Oxidative stress will never see it coming!

Bonda DJ, Liu G, Men P, Perry G, Smith MA, Zhu X.

CNS Neurol Disord Drug Targets. 2012 Feb;11(1):81-5. Review.

2.

Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

Liu G, Men P, Perry G, Smith MA.

Methods Mol Biol. 2010;610:123-44. doi: 10.1007/978-1-60327-029-8_8.

3.

Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease.

Liu G, Men P, Perry G, Smith MA.

Prog Brain Res. 2009;180:97-108. doi: 10.1016/S0079-6123(08)80005-2. Epub 2009 Dec 8. Review.

PMID:
20302830
4.

Nanoparticle and other metal chelation therapeutics in Alzheimer disease.

Liu G, Garrett MR, Men P, Zhu X, Perry G, Smith MA.

Biochim Biophys Acta. 2005 Sep 25;1741(3):246-52. Review.

5.

Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.

Liu G, Men P, Kudo W, Perry G, Smith MA.

Neurosci Lett. 2009 May 22;455(3):187-90. doi: 10.1016/j.neulet.2009.03.064. Epub 2009 Mar 25.

6.

Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.

Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA.

Neurosci Lett. 2006 Oct 9;406(3):189-93. Epub 2006 Aug 21.

PMID:
16919875
7.

Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.

Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, Mumper RJ.

Eur J Pharm Biopharm. 2005 Feb;59(2):263-72.

PMID:
15661498
8.

Amyloid-beta metal interaction and metal chelation.

Cuajungco MP, Frederickson CJ, Bush AI.

Subcell Biochem. 2005;38:235-54. Review.

PMID:
15709482
9.

Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease.

Robert A, Liu Y, Nguyen M, Meunier B.

Acc Chem Res. 2015 May 19;48(5):1332-9. doi: 10.1021/acs.accounts.5b00119. Epub 2015 May 6.

PMID:
25946460
10.

Neurotherapeutic applications of nanoparticles in Alzheimer's disease.

Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C.

J Control Release. 2011 Jun 10;152(2):208-31. doi: 10.1016/j.jconrel.2010.11.033. Epub 2010 Dec 4. Review.

PMID:
21134407
11.
12.

Challenges associated with metal chelation therapy in Alzheimer's disease.

Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, Srinivas P, Sambamurti K, Rao KJ, Scancar J, Messori L, Zecca L, Zatta P.

J Alzheimers Dis. 2009;17(3):457-68. doi: 10.3233/JAD-2009-1068. Review.

13.

Nano drug delivery systems: a new paradigm for treating metal toxicity.

Yadav A, Flora SJ.

Expert Opin Drug Deliv. 2016 Jun;13(6):831-41. doi: 10.1517/17425247.2016.1160890. Epub 2016 Mar 31. Review.

PMID:
27030893
14.

Redox-active metals, oxidative stress, and Alzheimer's disease pathology.

Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT.

Ann N Y Acad Sci. 2004 Mar;1012:153-63. Review.

PMID:
15105262
15.

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

Squitti R, Rossini PM, Cassetta E, Moffa F, Pasqualetti P, Cortesi M, Colloca A, Rossi L, Finazzi-Agró A.

Eur J Clin Invest. 2002 Jan;32(1):51-9.

PMID:
11851727
16.

Encapsulation of the flavonoid quercetin with an arsenic chelator into nanocapsules enables the simultaneous delivery of hydrophobic and hydrophilic drugs with a synergistic effect against chronic arsenic accumulation and oxidative stress.

Ghosh S, Dungdung SR, Chowdhury ST, Mandal AK, Sarkar S, Ghosh D, Das N.

Free Radic Biol Med. 2011 Nov 15;51(10):1893-902. doi: 10.1016/j.freeradbiomed.2011.08.019. Epub 2011 Aug 26.

PMID:
21914470
18.

Metal chelation as a potential therapy for Alzheimer's disease.

Cuajungco MP, Fagét KY, Huang X, Tanzi RE, Bush AI.

Ann N Y Acad Sci. 2000;920:292-304. Review.

PMID:
11193167
19.

Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease.

Yin T, Yang L, Liu Y, Zhou X, Sun J, Liu J.

Acta Biomater. 2015 Oct;25:172-83. doi: 10.1016/j.actbio.2015.06.035. Epub 2015 Jul 2.

PMID:
26143603
20.

Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies.

Kamalinia G, Khodagholi F, Atyabi F, Amini M, Shaerzadeh F, Sharifzadeh M, Dinarvand R.

Mol Pharm. 2013 Dec 2;10(12):4418-31. doi: 10.1021/mp4002014. Epub 2013 Oct 28.

PMID:
24063264

Supplemental Content

Support Center